Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- In April 2024, the company entered into a definitive agreement to acquire Zoetis's MFA product portfolio, with completion expected between October and December 2024.
- In 2023, another 14 countries reported outbreaks of Highly Pathogenic Avian Influenza, indicating ongoing disease spread.
- The FDA issued a final order to revoke the approved method for detecting carbadox residues, impacting regulatory compliance.
- The ongoing conflicts between Israel and Hamas and between Russia and Ukraine may disrupt international trade and impact financial condition.
- As of June 30, 2024, the company had outstanding indebtedness of $256 million under its 2024 Credit Facilities, reflecting significant financial obligations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1069899&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.